The application is for a novel psychedelic-based combination, of Clearmind’s MEAI and SciSparc’s Cannamide Tel Aviv, Israel / Vancouver, Canada, April 21, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated…

Source

Previous articlePsychedelics Weekly – The Church of Psilomethoxin Controversy, Psychedelics for Long COVID, and The Growth of Bicycle Day
Next articleBetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California